These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11365973)

  • 41. Protease inhibitor expanded access.
    Smart T
    GMHC Treat Issues; 1995 Jun; 9(6):3. PubMed ID: 11362689
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
    von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J
    Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resistance slow to emerge in combination therapy.
    AIDS Patient Care; 1995 Dec; 9(6):303-4. PubMed ID: 11361441
    [No Abstract]   [Full Text] [Related]  

  • 44. LaCARP seeks patients for study that will compare protease inhibitors.
    Fac Notes (New Orleans La); 1998; 10(6):6. PubMed ID: 11366144
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Garlic supplements found to lower saquinavir levels.
    TreatmentUpdate; 2001; 12(12):17-8. PubMed ID: 11570085
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
    Marcelin AG; Flandre P; de Mendoza C; Roquebert B; Peytavin G; Valer L; Wirden M; Abbas S; Katlama C; Soriano V; Calvez V
    Antivir Ther; 2007; 12(2):247-52. PubMed ID: 17503666
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What they say about: protease inhibitors.
    Posit Aware; 2000; 11(1):48-54. PubMed ID: 11366351
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Searching for the right dose of ritonavir-saquinavir.
    TreatmentUpdate; 2001 Sep; 13(5):3. PubMed ID: 11768860
    [No Abstract]   [Full Text] [Related]  

  • 50. HIV drug may raise hopes.
    Nurs Stand; 1996 Nov; 11(7):28. PubMed ID: 8945319
    [No Abstract]   [Full Text] [Related]  

  • 51. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A further option in PI therapy. Approval of a new protease inhibitor in the USA].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():30. PubMed ID: 16385868
    [No Abstract]   [Full Text] [Related]  

  • 54. San Franscisco area: important cyclosporin study recruiting.
    James JS
    AIDS Treat News; 1999 Mar; (No 315):8. PubMed ID: 11366562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Upcoming compassionate use programs for two new antiretrovirals will begin this fall.
    Schouten J
    STEP Perspect; 1999; 99(3):16. PubMed ID: 11366864
    [TBL] [Abstract][Full Text] [Related]  

  • 56. From grapefruit juice to ritonavir.
    TreatmentUpdate; 2001; 12(12):5-6. PubMed ID: 11570093
    [No Abstract]   [Full Text] [Related]  

  • 57. Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients.
    Autar RS; Wit FW; Sankote J; Sutthichom D; Kimenai E; Hassink E; Hill A; Cooper DA; Phanuphak P; Lange JM; Burger DM; Ruxrungtham K
    AIDS; 2007 Jul; 21(12):1535-9. PubMed ID: 17630547
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The younger generation.
    Jefferys R; Forataro K
    Body Posit; 1999 Aug; 12(8):15-6. PubMed ID: 11367065
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A review of low-dose ritonavir in protease inhibitor combination therapy.
    Cooper CL; van Heeswijk RP; Gallicano K; Cameron DW
    Clin Infect Dis; 2003 Jun; 36(12):1585-92. PubMed ID: 12802760
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin.
    Losso MH; Lourtau LD; Toibaro JJ; Saenz C; González C
    Antivir Ther; 2004 Dec; 9(6):1031-3. PubMed ID: 15651762
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.